Article

Dr. Stuart Goldberg Answers Common Questions From CML Patients

Stuart Goldberg, hematologist/oncologist at John Theurer Cancer Center, discusses some of the common questions he gets from his patients with chronic myeloid leukemia.

Stuart Goldberg, hematologist/oncologist at John Theurer Cancer Center, discusses some of the common questions he gets from his patients with chronic myeloid leukemia.

Goldberg discusses common topics, which include mortality risk, side effects, monitoring of disease and deep remissions, and how he approaches those questions with an informed discussion.

Related Videos
Image of man with grey hair.
Image of woman with black hair.
Image of a smiling woman with brown hair.
Image of a woman with short brown hair, wearing glasses.
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a black button-up shirt.
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Related Content
Image of a smiling woman with brown hair.
December 20th 2024

How to Self Advocate When Insurance Says No to Cancer Treatment Coverage

Ashley Chan
When insurance denies coverage of cancer treatment, patients with cancer don’t need to take no for an answer, an expert explained.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of Dr. Brandon Blue.
December 17th 2024

Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey

Alex Biese
Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of blood test.
December 10th 2024

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

Ariana Pelosci
The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.
Illustration of blood cells.
December 9th 2024

Calquence Plus Venclexta Combo May Improve Survival in Frontline CLL

Kristie L. Kahl
Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.